Brise Pharma Announces Completion of Hundred-Million-Yuan Series Angel Financing to Advance Innovative Pain Therapeutics Pipeline

Recently, Brise Pharmaceuticals (Shanghai) Co., Ltd. (“Brise Pharmaceuticals”), an emerging innovator in the development of novel drugs for pain management, officially announced the completion of its angel financing round, amounting to hundreds of millions of yuan. The round was co-led by Qiming Venture Partners and Boyuan Capital, with Jianyi Capital participating as a follow-on investor. The raised funds will be utilized to advance its globally leading R&D pipeline for pain treatments, as well as to support collaborative development, mergers and acquisitions, and licensing-in of innovative technological products.

Brise Pharmaceuticals is committed to becoming a global leader in the discovery, development, and commercialization of innovative analgesic drugs, providing physicians with rational and effective pain management solutions to alleviate patient suffering. The company focuses on targets within the pain field that have well-defined human genetic and pathological mechanisms, selecting optimal therapeutic modalities and routes of administration. By leveraging in-house R&D, collaborative development, and mergers and acquisitions, Brise Pharmaceuticals is building a globally leading pipeline for pain treatment research and development, while employing flexible clinical trial strategies to enhance drug accessibility and commercial value.

Furthermore, as pain serves as a warning signal for the body, its complete elimination may lead to other serious harms. Given that the etiologies of chronic pain conditions are complex and vary across different diseases, monotherapy with pharmaceuticals alone is generally insufficient to meet the needs of long-term pain control. Brise Pharmaceuticals is seeking partners with innovative technology platforms and products in medical devices, digital therapeutics, and health management. Leveraging its strengths in drug development and clinical practice, the company aims to collaborate with these partners to develop safer, more effective, and sustainable comprehensive pain management solutions.

In summary, Brise Pharmaceuticals will leverage its self-developed and acquired global-leading pipeline of pain therapeutics, along with comprehensive management solutions co-developed with partners, to establish a commercialization infrastructure in China while actively pursuing the overseas commercialization of its international rights.

Dr. Li Guochun, Founder and CEO of Brise PharmaceuticalsHe stated, “We extend our sincere gratitude to all the distinguished investors for their recognition and support of Brise Pharmaceuticals. A decade ago, I was involved in an innovative pain management drug project at a major U.S. pharmaceutical company, and I have closely monitored advancements in this field ever since. For many years, no blockbuster drugs have emerged internationally, constrained by limited understanding of disease mechanisms and a lack of safe drug delivery methods. In recent years, as clinical understanding of pain has deepened, the field of pain treatment is gradually emerging from the ‘valley of death’ in R&D. Facing this vast blue-ocean market with tremendous potential, Brise Pharmaceuticals is confident in becoming a global leader in innovative analgesic medications.”

Dr. Chen Kan, Partner at Qiming Venture Partners“The clinical demand in the field of pain management is continuously increasing, presenting substantial market potential. As industry understanding of pain deepens and technological R&D achieves breakthroughs, the development of analgesic drugs is entering a period of significant growth. Led by Dr. Li Guochun, the team at Brise Pharmaceuticals combines a global perspective with extensive industry experience, demonstrating accurate judgment and profound insights into technological advancements both domestically and internationally. Qiming Venture Partners firmly believes in the development potential of Brise Pharmaceuticals in the field of pain management and will provide long-term support for its growth.”

Dr. Guo Jiacong, Executive Director of Boyuan Capital“Significant unmet clinical needs remain in the field of pain management, and effective pain control delivers substantial clinical, commercial, and social value. Boyuan Capital has long focused on the pain management sector, with investments in innovative medical device companies such as Shenluo Medical. We highly recognize the strategic vision and execution capabilities of Brise Pharmaceuticals’ management team. We look forward to providing robust support in areas such as industry collaboration and integration of upstream and downstream resources, accompanying Brise Pharmaceuticals as it grows into an internationally leading innovator in the development of novel therapeutics for pain management.”

Jianyi Capital“It has always been our investment philosophy to seek out innovative niche areas with unmet clinical needs. Pain is a clinically common yet extremely complex condition. In-depth research into pain signaling pathways has identified numerous druggable targets, and accelerating the clinical application of these new targets presents a significant opportunity for the development of innovative pharmaceutical companies. Brise Pharmaceuticals is one of the few companies in China dedicated to the R&D of innovative pain therapeutics, boasting a robust product pipeline and a highly experienced founding team. Jianyi Capital is honored to have participated in this angel round of financing, and we hope to contribute to the company’s growth and development.”

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages ten U.S. dollar funds and six RMB funds, with total assets under management reaching $6.2 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in industries such as TMT and Healthcare. To date, Qiming Venture Partners has invested in more than 430 high-growth innovative enterprises, among which over 170 have exited through listings on exchanges including the New York Stock Exchange, NASDAQ, Hong Kong Stock Exchange, Taipei Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, as well as through mergers and acquisitions. More than 40 of these portfolio companies have become industry-recognized unicorns and super unicorns.

BioTrack Capital, established in 2017, is a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. Currently, BioTrack Capital manages two RMB funds and two USD funds, with total assets under management exceeding RMB 7 billion. More than just an investor, BioTrack Capital serves as a long-term partner to entrepreneurs. Since its inception, the firm has remained committed to an entrepreneur-centric approach, providing sustained support and active empowerment to exceptional founders in the healthcare sector, fostering an industry ecosystem, and cultivating the next generation of leading enterprises in China’s healthcare industry.

Shanghai Jianyi Private Equity Fund Management Co., Ltd. (formerly Sinopharm Capital) was established in 2012 by the former senior management team of Sinopharm Group under market-oriented mechanisms. It combines the strategic investment advantages of a Corporate Venture Capital (CVC) with the market-driven strengths of an independent Venture Capital (VC) fund, focusing on early-stage and growth-stage equity investments in the pharmaceutical and healthcare sectors. Leveraging its industrial resources to empower portfolio companies, Jianyi Capital has managed funds exceeding RMB 6.5 billion since its inception. Its investment portfolio comprehensively covers early-stage innovative ventures, growth-stage companies, and M&A consolidation projects, with investments in more than 80 leading enterprises in the pharmaceutical and healthcare fields. Adhering to the philosophy of “Sincerity, Professionalism, and Win-Win Cooperation,” Jianyi Capital is committed to accompanying its portfolio companies in their shared growth.